Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Diagnostic Hybrids

Diagnostic Hybrids
1982 FOUNDED
M&A STATUS
201-300 EMPLOYEES
M&A LATEST DEAL TYPE
$131M LATEST DEAL AMOUNT
Description

Developer of diagnostic cell cultures and virus detection kit systems used in the clinical diagnosis of infectious and autoimmune diseases. The company offers D3 FastPoint L-DFA influenza A/influenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patient's specimen. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Acquirer
Primary Office
  • 350 West State Street
  • Athens, OH 45701
  • United States

+1 (740) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Diagnostic Hybrids’s full profile, request a free trial.

Diagnostic Hybrids Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 19-Feb-2010 $131M 0000 00000 Completed Generating Revenue
1. Later Stage VC 11-Aug-2004 0000 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Diagnostic Hybrids Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Kenson Ventures Venture Capital Minority 000 0000 000000 0
Summit Partners Growth/Expansion Minority 000 0000 000000 0